Form 8-K Sage Therapeutics, Inc. For: Jul 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sage Therapeutics stock sinks after drug study failed
July 24, 2024 8:15 AM EDTSAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from a late-stage clinical trial for its drug SAGE-324 (BIIB124) for essential tremor (ET).
The Phase 2 KINETIC 2 study failed to meet its primary endpoint, which measured improvement in upper limb tremors. Additionally, no... More
